The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1533
Guselkumab (Tremfya) for Psoriasis
The full article is available to subscribers Subscriber Login   

The FDA has approved the interleukin (IL)-23 blocker guselkumab (Tremfya – Janssen) for treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Guselkumab is the first selective IL-23 blocker to become available in the US.

MECHANISM OF ACTION — IL-23 is a cytokine involved in normal inflammatory and immune responses. Guselkumab is a fully human monoclonal IgG1 antibody that selectively binds to the p19 subunit of IL-23, inhibiting it from binding to the IL-23 receptor and preventing downstream release of pro-inflammatory cytokines (such as IL-17A) and chemokines.

STANDARD TREATMENT — Plaque psoriasis is a chronic, inflammatory, immune-mediated disorder. Mild to moderate psoriasis is generally treated with topical corticosteroids. Topical vitamin D analogs and the retinoid tazarotene (Tazorac, and others) ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Guselkumab (Tremfya) for Psoriasis
Article code: 1533a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian